Nexium Control 28 Tablet Pack

Go To

Improved value and convenience
How to recommend Nexium Control 28 tablet pack
Why recommend Nexium Control?
Recommend for patients with frequent heartburn
Nexium Control Product Information

Improved value & convenience for patients with recurrent frequent heartburn

The Nexium Control 28 tablets pack offers benefits for patients who have used esomeprazole with positive results:

Improved value at a lower cost per tablet
Product available on hand for future episodes
Meets the shopper needs for larger packs¹

Flowchart of frequent and occasional heartburn

How to recommend the 28 tablet pack size for Nexium Control

One tablet per day
Maximum 14 consecutive days use
If symptoms do not resolve or get worse after 14 days refer to a GP
Should symptoms recur after 3 months, patients may restart a further treatment course. If less than three months after previous treatment, it is advisory to refer patients to seek advice from a GP²

Ask patients how often they suffer – more than once a week is classed as frequent heartburn³
Patients with frequent heartburn may benefit from a PPI such as Nexium Control to give the oesophagus a ‘holiday’ from acid and reduce sensitivity⁴

Learn more about the role of frequency in heartburn treatment recommendations.

Learn more

Recommend Nexium Control to patients with heartburn more than once per week

Nexium Control 28 tablet pack

For patients with recurrent frequent heartburn who have used esomeprazole successfully and seek the value and convenience of a larger pack.

Nexium Control 7 and 14 tablet packs

Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.

Nexium Control 14 Capsule pack

Easy-to swallow mini capsules. Complete 14-day treatment course.

Nexium Control Product Information

Product Information

Product Information: Please consult the Summary of Product Characteristics for full product information. Nexium Control 20 mg gastro-resistant tablets and Nexium Control 20 mg gastro-resistant hard capsules (esomeprazole). Indications: The short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: One tablet or capsule per day. May need to be taken for 2-3 consecutive days to achieve symptom improvement. Maximum treatment duration: up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Precautions: Refer to doctor if patient has: Jaundice or severe liver disease, significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis, previous gastric ulcer or gastrointestinal surgery, continuous treatment of indigestion or heartburn for 4 or more weeks, or is over 55 years old with new or recently changed symptoms. Not suitable for long term use. May lead to a slightly increased risk of gastrointestinal infections e.g. Salmonella and Campylobacter and in hospitalised patients, possibly Clostridium difficile. Consult doctor prior to having an endoscopy or urea breath test. Co-administration with atazanavir is not recommended. Interactions with medicinal products metabolised through CYP2C19 should be considered. The use of esomeprazole with clopidogrel should be discouraged. Do not take another PPI or H2 antagonist concomitantly. Increased Chromogranin A (CgA) can interfere with neuroendocrine tumour investigations. Stop Nexium Control at least 5 days before CgA measurements. Very infrequent cases of SCLE may occur. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly. Healthcare professional should consider stopping treatment. Contain sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product. Capsules only: Contain Allura red AC (E129) which can cause allergic reactions. Side effects: Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). For uncommon, rare, very rare and other side effects please refer to the SPC for full information. Legal category: Supply through pharmacy only. Product licence number: Tablets: EU/1/13/860/001; EU/1/13/860/002; EU/1/13/860/004. Capsules: EU/1/13/860/003; and EU/1/13/860/005. MAH: GlaxoSmithKline Dungarvan Limited, Knockbrack, Dungarvan, County Waterford, Ireland. Additional information is available upon request. Text prepared: June 2024.

Contains esomeprazole. Always read the label/leaflet.